Log in

Kura Oncology Stock Forecast, Price & News

-0.41 (-1.20 %)
(As of 12/2/2020 12:00 AM ET)
Today's Range
Now: $33.69
50-Day Range
MA: $34.83
52-Week Range
Now: $33.69
Volume679,257 shs
Average Volume582,264 shs
Market Capitalization$1.91 billion
P/E RatioN/A
Dividend YieldN/A
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KURA



Sales & Book Value

Annual SalesN/A
Book Value$5.40 per share


Net Income$-63,140,000.00


Market Cap$1.91 billion
Next Earnings Date2/23/2021 (Estimated)
-0.41 (-1.20 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

How has Kura Oncology's stock been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 249.1% and is now trading at $33.69.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Kura Oncology?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kura Oncology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Kura Oncology

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.03.
View Kura Oncology's earnings history

What price target have analysts set for KURA?

11 Wall Street analysts have issued 12 month target prices for Kura Oncology's shares. Their forecasts range from $24.00 to $43.00. On average, they anticipate Kura Oncology's share price to reach $34.33 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts' price targets for Kura Oncology

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 4,330,000 shares, an increase of 25.9% from the October 31st total of 3,440,000 shares. Based on an average daily trading volume, of 724,000 shares, the short-interest ratio is currently 6.0 days.
View Kura Oncology's Short Interest

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 51, Pay $908.26k)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer (Age 47, Pay $630.86k)
  • Ms. Kathleen Ford, Chief Operating Officer (Age 73, Pay $492.28k)
  • Mr. James E. Basta J.D., Esq., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 54, Pay $168.94k)
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
  • Dr. Blake Tomkinson M.B.A., Ph.D., Head of Portfolio Strategy & Program Management
  • Ms. Kirsten Flowers, Chief Commercial Officer (Age 45)
  • Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
  • Dr. Stephen Dale M.D., Chief Medical Officer

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.79%), State Street Corp (3.08%), Victory Capital Management Inc. (3.03%), Boxer Capital LLC (1.85%), Candriam Luxembourg S.C.A. (0.96%) and Polar Capital LLP (0.88%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Ecor1 Capital Fund Qualified,, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Victory Capital Management Inc., Sphera Funds Management LTD., Alethea Capital Management LLC, AXA S.A., Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, and J. Goldman & Co LP. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology

Which institutional investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including Polar Capital LLP, Polar Capital LLP, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Federated Hermes Inc., Boxer Capital LLC, DekaBank Deutsche Girozentrale, and Voloridge Investment Management LLC.
View insider buying and selling activity for Kura Oncology

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $33.69.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $1.91 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 71 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.